OXiGENE Announces Corporate Goals for 2005: Company Plans to Move CA4P into Later-stage Clinical Studies in Two Cancer Indications in 2005 WALTHAM, Mass.--(BUSINESS WIRE)--Jan. 7, 2005--OXiGENE, Inc. (Nasdaq: OXGN, XSSE: OXGN), developing novel small-molecule therapeutics to treat cancer and
OXiGENE's CA4P Demonstrates Anti-tumor Activity in Preclinical Retinoblastoma Model- Study Published in Investigative Ophthalmology & Visual Science - WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 4, 2005--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) announced today the publication of a preclinical study using
OXiGENE Sets Conference Call and Webcast for Fourth Quarter and Full-Year 2004 Results WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 9, 2005--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) invites the public to listen to a live audio webcast of the Company's fourth quarter and full-year 2004 financial results
OXiGENE's Lead Compound CA4P Enhances the Anti-Tumor Activity of Avastin in Pre-clinical Studies Data Presented at International Symposium on Anti-Angiogenic Agents Conference in La Jolla WALTHAM, Mass., Feb 14, 2005 (BUSINESS WIRE) -- OXiGENE, Inc. (Nasdaq: OXGN, XSSE: OXGN) announced today that
OXiGENE to Present at Roth Capital Partners 17th Annual OC Conference: February 22nd Presentation Available via Live Webcast WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 18, 2005--OXiGENE, Inc. (NASDAQ: OXGN) (XSSE: OXGN), today announced that President and Chief Executive Officer Fred Driscoll will
OXiGENE to Participate on Distinguished Anti-angiogenesis Panel at BIO CEO & Investor Conference WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 22, 2005--OXiGENE Inc, (NASDAQ: OXGN, SSE: OXGN) today announced that Dai Chaplin, Chief Scientific Officer of OXiGENE, will participate in a focus session entitled
OXiGENE Reports Fourth-Quarter and Year-End 2004 Financial Results WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 25, 2005--Accomplishments in 2004: Initiated two new clinical oncology trials with CA4P; CA4P now studied in seven clinical oncology trials Initiated a Phase II trial of CA4P in myopic macular
OXiGENE to Present at Wells Fargo Securities 2005 HealthCare Conference: March 2nd Presentation Available via Live Webcast WALTHAM, Mass.--(BUSINESS WIRE)--March 1, 2005--OXiGENE, Inc. (NASDAQ:OXGN, XSSE:OXGN), a leading developer of biopharmaceutical compounds designed to target aberrant blood
OXiGENE Announces Sale of $15 Million of Common Stock WALTHAM, Mass.--(BUSINESS WIRE)--March 4, 2005--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) today announced that the Company will receive gross proceeds of $15 million from the sale of 3,336,117 shares of its common stock, pursuant to OXiGENE's
OXiGENE to Present at 3rd International Symposium on Targeted Anticancer Therapies WALTHAM, Mass.--(BUSINESS WIRE)--March 4, 2005--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a leading developer of biopharmaceutical compounds designed to target aberrant blood vessels within solid tumor cancers and
